Bortezomib: a new therapeutic option for POEMS syndrome.

Clicks: 276
ID: 79816
2010
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated.We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib.After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically.Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.
Reference Key
kaygusuz2010bortezomibeuropean Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kaygusuz, Isik;Tezcan, Hakan;Cetiner, Mustafa;Kocakaya, Ozan;Uzay, Ant;Bayik, Mahmut;
Journal European journal of haematology
Year 2010
DOI
10.1111/j.1600-0609.2009.01341.x
URL
Keywords
mediterranean region forest management geographic information systems deadwood reference values physiographic parameters

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.